Report Overview

The global rubella diagnostic testing market was pegged at US$ 4.69 billion in 2021 and is expected to witness a CAGR of 4.5% during the forecast period.

Market Fundamentals 

Rubella is an acute, infectious viral infection that affects both children and adults and results in a low fever and rash. Pregnancy-related infections, particularly those that occur in the first trimester, increase the risk of miscarriage, stillbirth, foetal death, and congenital deformities in the baby. Globally, there has been an increase in the number of cases of rubella. The Centres for Disease Control and Prevention (CDC) reports that congenital rubella syndrome (CRS) affects more than 100,000 children worldwide each year, making rubella a major public health concern. Up to 90% of babies born to mothers who contracted rubella during the first three months of pregnancy have congenital rubella syndrome. In order to reduce the number of cases of rubella, governments around the world are implementing vaccination programmes. For instance, India launched the Intensified Mission Indradhanush (IMI) 4.0 in 2022 with the aim of expanding the reach of the universal immunisation programme, under which more than 3 crore pregnant women and 2.6 crore children receive vaccinations annually.

[673423423]

Market Dynamics

Government efforts to control the rubella virus, rising rates of the disease, and the introduction of cutting-edge point-of-care diagnostic technologies are the main drivers of the growth of the rubella diagnostic testing market, which is anticipated to accelerate over the course of the forecast period. Furthermore, globally, the prevalence of the rubella virus is rising. The World Health Organization (WHO) reports that 10798 instances of diagnostically proven rubella were recorded in 2021, compared to roughly 10361 cases reported with a confirmed diagnosis in 2020. 

Market Ecosystem

The global rubella diagnostic testing has been analysed into three perspectives into testing techniques, application and region.

Rubella Diagnostic Testing Market by Testing Techniques

[8798654]

Based on testing techniques, the global rubella diagnostic testing has been segmented into latex agglutination, enzyme immunoassay (EIA), radioimmunoassay (RIA), fluorescent immunoassay (FIA), and other testing techniques. The enzyme immunoassay (EIA) segment dominated the market during the forecast period. The standard test for the early diagnosis of rubella in a lab setting is the identification of rubella-specific immunoglobulin M (IgM) in serum. The most popular testing method utilising commercial enzyme immunoassay (EIA) kits is IgM testing. The blood test finds antibodies that the immune system produces to combat the rubella virus, these antibodies last for years in the bloodstream.

Rubella Diagnostic Testing Market by Application

Based on testing techniques, the global rubella diagnostic testing has been segmented into hospital, laboratories, and others. The hospital segment dominated the global rubella diagnostic testing market during owing to increasing cases of rubella. The increase in hospitals and the use of technologies for quick results are attributed with the segment's growth. Government financing and policies are also contributing to the market's rapid growth of the healthcare sector. Infectious infections are becoming more common, which is projected to spur market expansion in the years to come. These reasons are projected to fuel the expansion of rubella diagnostics during the forecast period as the infectious disease is spreading and affecting markets and values.

Rubella Diagnostic Testing Market by Region

Based on testing techniques, the global rubella diagnostic testing has been segmented into North America, Europe, Asia Pacific and Rest of the World. The rising incidence of rubella infection in this region made Europe one of the top markets in terms of revenue share. Colombia and Latin America are free of the rubella virus, according to the Pan American Health Organization (PAHO) and the World Health Organization (WHO). However, developing countries like Africa and South East Asia continue to experience rubella epidemics. There is no rubella vaccination available in these areas. The majority of cases of rubella infection are found in Syria, Macedonia, Thailand, Timor Leste, Tajikistan, and Macedonia.

Competitive Landscape

Some of the prominent market players in the global rubella diagnostic testing include 

• Ortho Clinical Diagnostics
• Abbott Laboratories 
• Merck & Co.
• Siemens AG
• GlaxoSmithKline plc.
• Hoffmann La Roche Ltd.
• Bio Rad Laboratories, Inc.
• BioMerieux SA 
• Beckman Coulter Inc.
• Thermo Fisher Scientific Inc.
• Johnson & Johnson Diagnostics, Inc.
• Zenith Healthcare Ltd. 
• Novartis Diagnostics
• ZEUS Scientific Inc. 
• Biokit SA.

The market under study is dominated by a few number of significant players, and the majority of these businesses are concentrating on the creation of new technologies in order to gain the largest possible market share.

Strategic development

• In January 2019, The BioPlex2200 MMRV IgG kit uses a multiplex flow immunoassay to detect IgG antibodies to the measles (rubeola), mumps, rubella (German measles), and varicella-zoster virus simultaneously and qualitatively (VZV). The system's ground-breaking eFlexTM software allows up to four assays to be run concurrently with add-on tests without the need for sample repetitions.
• In November 2018, to increase the company's presence in the Chinese market, bioMérieux acquired the majority of the shares in Suzhou Hybiome Biomedical Engineering Co. Ltd.

Frequently Asked Questions About This Report